Key facts
- Notable investors include Goldport Capital, Sinochem Capital, Xi'an Royal-Power Asset Management, Xihu VC, Zhejiang Xianju Pharmaceutical Company.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for XHSynbio
- ·The full record, as it builds
Funding rounds
No funding rounds for XHSynbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About XHSynbio
Developer of pharmaceutical enzymes and chiral chemicals intended for industrial biotechnology and pharmaceutical manufacturing in China. The company's range of products includes enzyme preparations, chiral drug intermediates, nutritional additives, fermentation-derived compounds, specialty reagents and active pharmaceutical ingredients, thereby enabling high-value production through advanced biotechnological processes.
- Sector
- Materials and Resources
- HQ
- Hangzhou, China
- Founded
- 2015
- Website
- xhsynbio.com/
- Ownership
- Privately Held (backing)
XHSynbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in XHSynbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on XHSynbio in its N-PORT filings yet. We sweep new filings monthly.